ABSTRACT
Nasal continuous positive airway pressure (nCPAP) is one of the most commonly used non-invasive respiratory support modes in neonates with transient tachypnea of the newborn (TTN). Non-invasive high-frequency oscillatory ventilation (nHFOV) is a non-invasive respiratory support mode that has been increasingly used in neonatal respiratory disorders. This prospective randomized controlled study compared the efficacy of nHFOV and nCPAP in reducing the duration of non-invasive respiratory support. Late preterm and term infants > 34 weeks' gestation were included in the study. The infants were randomly assigned to receive either nHFOV or nCPAP. Treatment was started with standard settings in both groups. Infants who met treatment failure criteria were switched to nasal intermittent mandatory ventilation for further positive-pressure support. A total of 60 infants were included in the study. Thirty of these infants were included in the nHFOV group and 30 were included in the nCPAP group. The median duration of non-invasive respiratory support was not significantly different between the two groups (21 h [IQR: 16-68] for nHFOV vs 15 h [IQR: 11-33] for nCPAP; p = 0.09). However, after adjusting for potential confounders, nHFOV was associated with a shorter duration of non-invasive respiratory support than nCPAP (adjusted mean difference: 16.3 h; 95% CI: 0.7 to 31.9; p = 0.04). nHFOV was well tolerated and did not increase the risk of complications. Conclusion: Our findings suggest that nHFOV is an effective and safe ventilation mode for late preterm and term neonates with TTN. Trial registry: Clinicaltrials.gov (NCT03006354). Date of registration: December 30, 2016. What is Known: ⢠nHFOV is a ventilation model that has been increasingly used for the management of RDS. ⢠TTN is one of the most common causes of neonatal respiratory distress. What is New: ⢠nHFOV is associated with shorter duration of non-invasive respiratory support and duration of oxygen support. ⢠nHFOV may be a safe and effective alternative to nCPAP for neonates with TTN.
Subject(s)
High-Frequency Ventilation , Noninvasive Ventilation , Respiratory Distress Syndrome, Newborn , Transient Tachypnea of the Newborn , Infant, Newborn , Infant , Humans , Transient Tachypnea of the Newborn/therapy , Transient Tachypnea of the Newborn/etiology , Infant, Premature , Prospective Studies , Intermittent Positive-Pressure Ventilation , Continuous Positive Airway Pressure/adverse effects , Respiratory Distress Syndrome, Newborn/therapy , Respiratory Distress Syndrome, Newborn/etiologyABSTRACT
BACKGROUND: The positive effects of steroids on lung development are well known, and 1,25-dihydroxy vitamin D3 has been shown to exert positive effects on fetal lung development. OBJECTIVE: We aimed to investigate the relationship between 25-hydroxyvitamin D [25(OH)D] levels and respiratory distress syndrome (RDS) in premature infants. METHODS: Infants aged ≤32 gestational weeks who were admitted to the neonatal intensive care unit (NICU) during 1 year were enrolled in this prospective study. 25(OH)D levels were obtained at the time of admission to NICU. Patients were divided into three groups according to their 25(OH)D levels: severe (group 1), moderate (group 2), and mild (group 3) 25(OH)D deficiencies. RESULTS: The study comprised 72 patients; of them, RDS was observed in 49 and not observed in 23 patients. The mean 25(OH)D levels were significantly lower in RDS patients (p=0.04). Multivariate analysis showed that patients with higher 25(OH)D levels can be preventive for the development of RDS (odds ratio 0.89; 95% confidence interval 0.8-0.99; p=0.04). CONCLUSION: Our study revealed that 25(OH)D deficiency is an independent risk factor for RDS in premature infants. However, further studies are necessary to explore the association between 25(OH)D deficiency and RDS.
Subject(s)
Infant, Premature/blood , Respiratory Distress Syndrome, Newborn/epidemiology , Vitamin D Deficiency/complications , Vitamin D/analogs & derivatives , Female , Gestational Age , Humans , Infant , Infant, Newborn , Male , Prospective Studies , Respiratory Distress Syndrome, Newborn/blood , Risk Factors , Tertiary Care Centers , Vitamin D/blood , Vitamin D Deficiency/epidemiologySubject(s)
Ectodermal Dysplasia/diagnosis , Skin/pathology , Ectodermal Dysplasia/pathology , Female , Humans , Infant, Newborn , TorsoSubject(s)
Calcinosis/diagnosis , Meconium , Peritonitis/diagnosis , Abdomen/pathology , Calcinosis/pathology , Female , Humans , Infant, Newborn , Peritonitis/pathologyABSTRACT
Gastro-esophageal reflux (GER) is one of the common problems of neonatal intensive care units. Although this condition does not always need to be treated, it occasionally causes clinically serious consequences. Initial management is medical; however, in some cases surgery might be required. A premature neonate with birth weight of 1370 grams was managed in our ICU. The patient was mechanical ventilator dependent due to GER. The patient needed Nissen fundoplication for successfully weaning off the ventilator.
ABSTRACT
Bartter's syndrome (BS) is an inherited renal tubular disorder characterized by hypokalemia, hypochloremic metabolic alkalosis, and hyperaldosteronism with normal blood pressure. A 22-year-old woman was referred at 23 week of gestation. Polyhydramnios was detected and the chloride level of the amniotic fluid was high. The mother was treated with indomethacin from 26 to 31 week of gestation. The newborn was delivered at 34 week of gestation. At 8th day of life, indomethacin was also started for the baby. After three days, a colonic perforation developed. Indomethacin-induced colon perforation is uncommon in antenatal Bartter's syndrome. This patient indicates that administration of indomethacin in both antenatal and/or early postnatal period may be associated with colonic perforation.
